In the realm of pharmaceutical manufacturing, a deep understanding of the chemical properties and specifications of Active Pharmaceutical Ingredients (APIs) is fundamental. Pimavanserin Tartrate, a critical API for treating Parkinson's disease psychosis, is no exception. This article outlines the key chemical characteristics and specifications that define high-quality Pimavanserin Tartrate, information vital for both manufacturers and researchers.

Pimavanserin Tartrate is characterized by its specific chemical structure, which dictates its unique pharmacological action. Its molecular formula, (C25H34FN3O2)2•C4H6O6, and molecular weight of approximately 1005.2 g/mol, are essential identifiers. The compound typically appears as a white to off-white solid powder. Understanding the Pimavanserin Tartrate chemical properties, such as solubility (freely soluble in DMSO, soluble in water, almost insoluble in ethanol), is crucial for its formulation into stable and effective dosage forms.

Key specifications for Pimavanserin Tartrate often include high purity levels, typically greater than 99% by HPLC, and strict limits on impurities, water content, heavy metals, and residual solvents. These parameters are rigorously monitored throughout the Pimavanserin Tartrate synthesis routes and are a critical part of the quality control process that supports its Pimavanserin Tartrate FDA approval. Adherence to these specifications ensures the safety and efficacy of the final pharmaceutical product.

For entities involved in API Pimavanserin Tartrate sourcing, detailed specification sheets are indispensable. These documents provide the necessary data to verify the API's quality and suitability for intended pharmaceutical applications. The reliable Pimavanserin Tartrate mechanism of action is directly linked to its chemical integrity, making adherence to specifications a cornerstone of its therapeutic value.

The continuous refinement of analytical methods allows for ever-increasing precision in characterizing APIs like Pimavanserin Tartrate. This commitment to quality assurance, from synthesis to final product testing, ensures that this vital compound can be reliably supplied to meet the needs of patients managing Parkinson's disease psychosis.